The following information was compiled in August 2024 and is subject to change as new research is conducted and as new information becomes available:

Description: Desalkylquazepam is a novel designer benzodiazepine bearing structural similarity to  diclazepam, desalkylgidazepam, phenazepam, and other NPS benzodiazepines. Desalkylquazepam can be used as a precursor in the synthesis of triazolobenzodiazepines. Desalkylquazepam was first detected in May 2024 by our laboratory and was confirmed after acquiring standard reference material.

Sample Source: Canton-Stark County Crime Laboratory (Canton, OH)

Sample Appearance: Blue powder

Pharmacology: No available pharmacological data for desalkylquazepam were discovered during our search. Structurally similar NPS benzodiazepines are active at the GABAA receptor and produce CNS depressant effects.

Toxicology: Desalkylquazepam has not yet been identified in toxicology cases to date at the CFSRE.

Drug Materials: Desalkylquazepam has been detected in one drug material to date at the CFSRE.

Demographics / Geographics: The drug material sample originated from Ohio. Desalkylquazepam was detected alongside NPS opioids (e.g., protonitazene) and adulterants (e.g., xylazine, diphenhydramine).

Legal Status: Desalkylquazepam is not explicitly scheduled in the United States.

Class:Benzodiazepine

Appearance:Blue powder

Formula:C15H10ClFN2S

MW:304.8 [M+]:304 [M+H]+:305.0310

IUPAC:7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepine-2-thione

Report Date:August 28, 2024